摘要
目的研讨聚乙二醇洛塞那肽与二甲双胍联合治疗对初诊肥胖2型糖尿病患者糖脂代谢的影响。方法选取初诊肥胖2型糖尿病患者80例,按照随机数表法划分为对照组和观察组,每组40例。对照组给予二甲双胍单药降糖,观察组基于对照组用药条件施加聚乙二醇洛塞那肽治疗。对比两组用药前后的血糖水平、血脂水平、机体应激反应指标水平以及用药安全性。结果用药后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白分别为(5.87±0.85)mmol/L、(8.62±1.38)mmol/L、(6.12±0.94)%,相比对照组的(7.02±1.14)mmol/L、(9.42±1.55)mmol/L、(7.23±1.21)%均更低,差异有统计学意义(P<0.05)。观察组高密度脂蛋白胆固醇为(1.13±0.17)mmol/L高于对照组的(1.05±0.15)mmol/L,总胆固醇、甘油三酯、低密度脂蛋白胆固醇分别为(4.05±0.71)、(1.87±0.56)、(2.21±0.65)mmol/L,均低于对照组的(4.69±0.83)、(2.23±0.68)、(2.69±0.71)mmol/L,差异有统计学意义(P<0.05)。观察组用药后血清超敏C反应蛋白、白细胞介素-6以及丙二醛分别为(6.24±0.65)mg/L、(5.79±0.71)ng/L、(4.70±0.89)μmol/L,相比对照组的(7.88±0.87)mg/L、(6.32±1.01)ng/L、(5.41±1.05)μmol/L均更低,差异有统计学意义(P<0.05)。两组发生药物不良反应的患者总占比对比,差异不具统计学意义(P>0.05)。结论聚乙二醇洛塞那肽与二甲双胍联合用于初诊肥胖2型糖尿病患者的治疗,能够更好地调节患者糖脂代谢状况,减轻机体应激反应,并保障用药安全。
Objective To explore the effect of combination therapy with polyethylene glycol loxenatide and metformin on glucose and lipid metabolism in newly diagnosed obese patients with type 2 diabetes mellitus.Methods A total of 80 newly diagnosed obese patients with type 2 diabetes mellitus were selected and divided into a control group and an observation group according to random number table method,with 40 cases in each group.The control group was given metformin monotherapy for hypoglycemia,and the observation group was given polyethylene glycol loxenatide based on the control group.The blood glucose level,blood lipid level,stress response indicators and drug safety were compared between the two groups before and after medication.Results After medication,the fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin in the observation group were(5.87±0.85)mmol/L,(8.62±1.38)mmol/L and(6.12±0.94)%,which were lower than(7.02±1.14)mmol/L,(9.42±1.55)mmol/L and(7.23±1.21)%in the control group,and the difference was statistically significant(P<0.05).The high density lipoprotein cholesterol in the observation group was(1.13±0.17)mmol/L,which was higher than(1.05±0.15)mmol/L in the control group;the total cholesterol,triglyceride and low density lipoprotein cholesterol in the observation group were(4.05±0.71),(1.87±0.56)and(2.21±0.65)mmol/L,which were lower than(4.69±0.83),(2.23±0.68)and(2.69±0.71)mmol/L in the control group;the difference was statistically significant(P<0.05).After medication,the serum levels of hypersensitive C-reactive protein,interleukin-6 and malondialdehyde in the observation group were(6.24±0.65)mg/L,(5.79±0.71)ng/L and(4.70±0.89)μmol/L,which were lower when compared with(7.88±0.87)mg/L,(6.32±1.01)ng/L and(5.41±1.05)μmol/L in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the percentage of adverse drug reactions between the two groups(P>0.05).Conclusion Polyethylene glycol loxenatide combined w
作者
屈昌会
史保强
王娟
姚焕焕
洪波
QU Chang-hui;SHI Bao-qiang;WANG Juan(Department of Endocrinology,Lianyungang Oriental Hospital(Affiliated Hospital of Xuzhou Medical University),Lianyungang 222042,China)
出处
《中国实用医药》
2024年第15期119-122,共4页
China Practical Medicine
关键词
肥胖2型糖尿病
聚乙二醇洛塞那肽
二甲双胍
糖脂代谢
安全性
Obese type 2 diabetes mellitus
Polyethylene glycol loxenatide
Metformin
Glucose and lipid metabolism
Safety
